Astra Industrial Group announces its Interim Financial Results for the Period Ending on 2019-09-30 ( Nine Months )

Element List	Current Quarter	Similar quarter for previous year	%Change	Previous Quarter	% Change
Sales/Revenue	443,270,965	405,345,434	9.356	485,730,440	-8.741
Gross Profit (Loss)	157,910,338	149,345,918	5.734	202,304,145	-21.944
Operational Profit (Loss)	24,526,666	4,001,642	512.915	46,088,451	-46.783
Net Profit (Loss) after Zakat and Tax	-14,623,304	-26,869,947	-45.577	15,776,188	-
Total Comprehensive Income	-17,861,711	-32,534,695	-45.099	19,617,322	-
All figures are in (Actual) Saudi Arabia, Riyals

Element List	Current Period	Similar period for previous year	%Change
Sales/Revenue	1,395,674,079	1,318,565,648	5.847
Gross Profit (Loss)	544,331,433	525,702,249	3.543
Operational Profit (Loss)	117,156,727	79,924,141	46.584
Net Profit (Loss) after Zakat and Tax	10,059,932	14,742,830	-31.763
Total Comprehensive Income	14,187,588	-10,954,623	-
Total Share Holders Equity (after Deducting Minority Equity)	1,072,387,554	1,071,749,162	0.059
Profit (Loss) per Share	0.13	0.18
All figures are in (Actual) Saudi Arabia, Riyals

Element List	Explanation
Increase (Decrease) in Net Profit for Current Quarter Compared to the Same Quarter of the Previous Year is Attributed to	Net Loss decreases in general due to:

A) Lower S&M expenses mainly in pharmaceuticals sector.

B) Lower gross loss in Power and Steel sector .

C) Higher gross profit in Specialty chemicals.

While noting that there are higher Financial charges and Zakat expenses.Increase (Decrease) in Net Profit for Current Quarter Compared to the Previous Quarter is Attributed to Net loss for the quarter is in general due to:

A) Lower sales and gross profit in following sectors:

1) Pharmaceuticals sector.

2) Specialty chemicals .

While noting that there are lower S&M expensesIncrease (Decrease) in Net Profit for Current Period Compared to the Similar Period of the Previous Year is Attributed to Net profit decreases in general due to:

A) Higher Financial charges.

B) Lower other income.

C) Higher zakat expenses.

While noting that there are higher sales and gross profit in Pharmaceuticals and Specialty chemicals sectors.Basis of the External Auditor's Opinion Unmodified opinionReclassification of Comparison Items Certain comparative figures for the previous period have been reclassified to be consistent with the presentation of the current period.Additional Information 1. Net Shareholders’ Equity at the end of the period is SR1,067,126,242/- compared to SR1,070,314,116/- at the end of the similar period last year with a decrease of 0.3%.

2. The company has adopted IFRS 16 for Leases from the initial application date of January 1st, 2019, with recognition of Right-of-use assets (SR51M), Lease liability (SR49M) and decrease in Prepayments (SR2M). Please refer to note 4 in the interim condensed consolidated financial statements.

The Capital Market Authority and Saudi Exchange take no responsibility for the contents of this disclosure, make no representations as to its accuracy or completeness, and expressly disclaim any liability whatsoever for any loss arising from, or incurred in reliance upon, any part of this disclosure, and the issuer accepts full responsibility for the accuracy of the information contained in it and confirms, having made all reasonable enquiries, that to the best of their knowledge and belief, there are no other facts or information the omission of which would make the disclosure misleading, incomplete or inaccurate.